Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues

Data monitoring safety board okays continuation of pivotal REGENERATE study in non-alcoholic steatohepatitis despite deaths of patients receiving Ocaliva for primary biliary cholangitis.